IL28B C/C GENOTYPE IS PREDICTIVE OF >= 1 LOG10 IU/ML REDUCTION IN PLASMA HCV RNA AFTER 4 WEEKS OF PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV) THERAPY: IMPLICATIONS FOR THE USE OF THE LEAD-IN STRATEGY FOR DIRECT-ACTING ANTIVIRAL-BASED TREATMENT REGIMENS

Alexander J Thompson, Paul J Clark, Hans L Tillmann, Keyur Patel, Susanna Naggie, F Fred Poordad, Eric Lawitz, Bruce R Bacon, John M Vierling, Stephanie Noviello, Clifford A Brass, Janice K Albrecht, David B Goldstein, John G McHutchison, Mark S Sulkowski, Andrew J Muir